---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-25-000199"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T02:36:46.178469+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vertex Pharmaceuticals authorizes $4.0B share repurchase program

## Summary
- Board authorized new $4.0B stock repurchase program (2025 Repurchase Program) with no expiration date.
- Combined with ~$775M remaining under 2023 program, total authorization rises to ~$4.775B.
- Repurchases may be made on open market or private transactions, including under Rule 10b5-1 plans.
- Company can discontinue program at any time; repurchases subject to market conditions and other opportunities.

## SEC filing metadata
- accession: 0000875320-25-000199
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532025000199/0000875320-25-000199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532025000199/vrtx-20250519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-25-000199
- JSON: https://secwatch.observer/filing/0000875320-25-000199.json
- Plain text: https://secwatch.observer/filing/0000875320-25-000199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.